These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Biological monitoring of a worker acutely exposed to MBOCA. Author: Osorio AM, Clapp D, Ward E, Wilson HK, Cocker J. Journal: Am J Ind Med; 1990; 18(5):577-89. PubMed ID: 2244630. Abstract: A 30 year-old male polyurethane worker was exposed to an accidental spill of 4,4'-methylene-bis-2-chloroaniline (MBOCA) at a plant producing MBOCA-cured plastic products. Exposure to MBOCA is significant in that this compound is a known animal carcinogen and a suspected human carcinogen. The employee was sprayed over his upper body and extremities with molten MBOCA while cleaning out a clogged hose from a MBOCA and polymer mixing machine. The subsequent environmental and medical evaluation of this episode included serial urinary MBOCA samples from the worker over a 2 week period to allow the calculation of a biological half-life for this compound. This worker experienced a very high dose of MBOCA as judged by his urinary MBOCA levels (peak value of 1,700 ppb 4 hours after exposure). There were no acute symptoms or other laboratory abnormalities noted. The kinetic evaluation resulted in a biological half-life for MBOCA in urine of approximately 23 hours. Assuming a one-compartment model, approximately 94% of an initial MBOCA dose will be eliminated within four days. This is the first report of kinetic analysis on urinary MBOCA excretion in humans. This information suggests that biological monitoring of the urine MBOCA concentrations in exposed workers may miss peak levels following an acute exposure unless the analyses of the urinary MBOCA are performed in a timely fashion. Recommendations to the company included: 1) installation of a warning system or lock-out device on the mixing machine to prevent the opening of the MBOCA hose prior to the release of pressure; and 2) annual medical surveillance of this individual for bladder cancer with urinalysis and urine cytology.[Abstract] [Full Text] [Related] [New Search]